Logo-ajpr

Indexing Information


 

Follower  of

 
Avicenna J Pharm Res. 2022;3(1): 32-36. doi: 10.34172/ajpr.2022.1065

Original Article

Comparison of the Total Side Effects of Injectable Disease-Modifying Drugs for the First-line Treatment of Relapsing-Remitting Multiple Sclerosis

Masoud Ghiasian 1 ORCID, Seyedeh Anis Rashidizad 2, Mojdeh Mohammadi 3, Younes Mohammadi 4, Sara Ataei 2 * ORCID

Cited by CrossRef: 0

1- Sahraian M, Emami S, Ataei S, Ghalandari N. Exploring autoimmune endocrine diseases induced by monoclonal antibodies used as multiple sclerosis pharmacotherapy: a systematic review. Naunyn-Schmiedeberg's Arch Pharmacol. 2024; [Crossref]